I acknowledge that the information on this site is for non-US customers only. The site may contain information that is not approved for your country.

Skip to content

For investors
Customer support
Webstore
Document portal

Diagnostic areas
Products
Services
Resources
About us

Contact us

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Post-transplantation
Devyser HLA Loss
One Lambda Devyser Chimerism Plus
One Lambda Devyser Chimerism NGS
One Lambda Devyser Accept cfDNA

Thalassemia
Devyser Thalassemia NGS
Devyser Thalassemia v2

Hereditary cancer
Devyser BRCA NGS
Devyser HBOC NGS
Devyser BRCA PALB2 NGS
Devyser LynchFAP

Fetal RHD screening NIPT
Devyser RHD

Transfusion medicine
Devyser Genomic Blood Typing

Cystic fibrosis
Devyser CFTR
Devyser CFTR Core
Devyser CFTR 68
Devyser CFTR Italia

Cardiovascular diseases
Devyser Thrombophilia
Devyser FH NGS
Devyser HFE
Devyser CVD

Male infertility
Devyser AZF Extension
Devyser AZF v2

Rapid aneuploidy analysis
Devyser Compact
Devyser Complete
Devyser Extend M1
Devyser Resolution 13
Devyser Resolution 18
Devyser Resolution 21
Devyser Resolution XY

Software
Advyser Solid organs
Advyser Chimerism
Amplicon Suite

Cybergene ChromoQuant®
Prenatal diagnostics
Pregnancy loss diagnostics
Male infertility diagnostics

Accessories
560 sizer orange
DEV-5 Dye set
Devyser Index plate A
Devyser Index plate LB-A
Devyser library clean
Devyser Index Plate LB-192

Devyser Genomic Laboratories

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products

Post-transplantation
Thalassemia
- Devyser Thalassemia NGS
- Devyser Thalassemia v2
Hereditary cancer
Fetal RHD screening NIPT
- Devyser RHD
Transfusion medicine
- Devyser Genomic Blood Typing
Cystic fibrosis
Cardiovascular diseases
Male infertility
- Devyser AZF Extension
- Devyser AZF v2
Rapid aneuploidy analysis
Software
Cybergene ChromoQuant®
Accessories

Services

Devyser Genomic Laboratories

Resources

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

About us

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

For investors
Customer support
Webstore
Document portal

The Devyser blog

Post-transplantation | August 28, 2026

Relapse after allogeneic stem cell transplantation: Is it time for routine HLA loss testing?

Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains one of the few potentially curative treatment options for patients with leukemia and other hematologic malignancies.1,2 By...

Find out more

Filter

Post-transplantation

Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients

Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...

Devyser Accept cfDNA demonstrates high performance in newly published peer-reviewed article

Devyser IVDR certified

Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvals

Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...

Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis

A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...

Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS products

Collaboration and distribution agreement with Thermo Fisher Scientific Thermo Fisher Scientific...

Simplify your lab workflow with single-tube NGS library preparation method

As a lab manager, you know the importance of streamlining workflows to maximize productivity and...

New more sensitive diagnostics protect transplanted kidney

With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...

Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with...

Assessment of Chimerism Testing by Next Generation Sequencing

Relapse of the underlying malignant disease is a major complication after hematopoietic stem cell...

Characteristics of a chimerism NGS assay with unmatched sensitivity

Devyser launches first NGS-based test for mixed chimerism

Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone...

Chimerism monitoring: is there a new gold standard on the horizon?

Chimerism monitoring after hematopoietic stem cell transplantation (HSCT) plays a key role in...

1 2 >

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products and services

Kits and reagents
Our services

Resources

Events & webinars
Knowledge hub
Whitepapers
Devyser blog
Calculator for Chimerism
Sequence coverage calculator
IFUs and certificates

About us

Our company
Contact us
Distributors
News and press
Career
Whistleblowing policy
Sustainability

Investors

Press releases
Reports

© Devyser 2026

Privacy policy | Legal terms | About cookies